As a medical enterprise, Daoqun Group attaches great importance to research and development innovation, and has increased investment in drug research and development in recent years, launching multiple innovative drugs and generic drugs. Among them, the 300mg aspirin enteric coated tablets independently developed by Daoqun have passed drug consistency evaluation and were approved for market in June this year. As one of the three classic drugs in the world, aspirin has the characteristics of classic safety and multiple effects. The aspirin enteric coated tablets developed by Daoqun not only meet the needs of fever patients for fever relief and pain relief, but also are more suitable for middle-aged and elderly people, and can prevent the occurrence of various chronic diseases.